Graphite Bio Q1 net loss $25.8M; on track to dose first SCD patient in H2 2022

LENZ Therapeutics, Inc.

2023-Q1 EPS reported -$0.48

Net loss $25.8M ($0.48 per share); R&D spend $18.2M, G&A $7.7M.
Cash, equivalents and investments $352.1M as of March 31, 2022; runway into Q4 2024.
GPH101 for sickle cell disease received FDA Fast Track Designation; first patient dosing target H2 2022, proof-of-concept data in 2023.
GPH102 for beta-thalassemia preclinical data presented at ASGCT; IND submission expected by mid-2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.